Dyne Therapeutics DYN Income Statement (2019-2026)

NASDAQ DYN
$16.21 -0.13 (-0.80%)
At close: Sep 29, 2026 · 4:00 PM EDT
Reported Financials

Dyne Therapeutics Quarterly Income Statement

Periods 28 quarters
Latest Jun 2026

Dyne Therapeutics reported net income of -$173.87M for the quarter ended Jun 2026. This income statement covers 28 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.)
51.48M51.57M51.65M51.73M51.91M55.64M58.31M61.01M61.32M61.47M87.09M100.12M101.75M102.32M113.63M114.34M142.61M128.44M165.20M165.67M
Operating items
Research & DevelopmentR&D
36.51M42.30M28.24M46.66M34.67M33.19M37.54M59.13M55.25M58.84M44.54M62.26M92.80M81.81M106.45M99.24M97.22M95.43M100.89M152.17M
Selling, General & AdministrativeSG&A
6.26M9.66M7.55M6.09M7.61M6.96M7.93M7.61M7.02M8.84M24.62M9.70M12.86M15.30M15.93M16.55M16.67M20.70M24.39M29.49M
Other Operating ExpensesOther Opex
-0.01M-0.03M0.01M-0.01M-0.02M-0.22M-0.37M-0.13M-0.70M0.51M-0.19M-0.74M-0.03M-0.09M-1.60M0.28M-0.29M-0.13M-0.09M
Operating ExpensesOpex
42.77M51.96M35.78M52.76M42.28M40.15M45.46M66.74M62.27M67.69M69.16M71.96M105.66M97.11M122.37M115.79M113.89M116.13M125.28M181.66M
Operating IncomeOp. Inc
-42.77M-51.96M-35.78M-52.76M-42.28M-40.15M-45.46M-66.74M-62.27M-67.69M-69.16M-71.96M-105.57M-97.11M-122.37M-115.79M-113.89M-116.13M-125.28M-181.66M
EBIT
-42.77M-51.96M-35.78M-52.76M-42.28M-40.15M-45.46M-66.74M-62.27M-67.69M-69.16M-71.96M-105.57M-97.11M-122.37M-115.79M-113.89M-116.13M-125.28M-181.66M
Non-operating items
Non Operating Interest Expenses
0.09M2.90M
Interest & Investment IncomeInt & Inv Inc
0.18M0.18M0.23M0.44M0.90M1.34M1.49M2.21M2.19M1.75M3.00M7.05M9.28M7.59M7.10M6.62M8.48M7.66M8.76M7.79M
Other Non Operating IncomeOther Non Op Inc.
0.18M0.17M0.20M0.45M0.89M1.32M1.28M1.83M2.06M1.05M3.51M6.86M8.53M7.57M7.01M4.93M5.85M4.17M4.42M3.10M
Net income details
EBT
-42.58M-51.78M-35.55M-52.31M-41.38M-38.80M-43.97M-64.53M-60.08M-65.94M-66.16M-64.91M-96.29M-89.52M-115.27M-109.26M-108.32M-108.47M-116.52M-173.87M
Profit After TaxPAT
-42.58M-51.78M-35.55M-52.31M-41.38M-38.80M-43.97M-64.53M-60.08M-65.94M-66.16M-64.91M-96.29M-89.52M-115.27M-109.26M-108.32M-108.47M-116.52M-173.87M
Income from Continuing OperationsIncome (Continuing)
-42.58M-51.78M-35.55M-52.31M-41.38M-38.80M-43.97M-64.53M-60.08M-65.94M-66.16M-64.91M-96.29M-89.52M-115.27M-109.26M-108.32M-108.47M-116.52M-173.87M
Consolidated Net IncomeConsol Net Inc.
-42.58M-51.78M-35.55M-52.31M-41.38M-38.80M-43.97M-64.53M-60.08M-65.94M-66.16M-64.91M-96.29M-89.52M-115.27M-109.26M-108.32M-108.47M-116.52M-173.87M
Income towards Parent CompanyParent Net Inc
-42.58M-51.79M-35.58M-52.30M-41.38M-38.83M-44.19M-64.90M-60.21M-66.64M-65.65M-65.10M-97.12M-89.54M-115.36M-110.86M-108.04M-111.95M-120.85M-178.56M
Net Income towards Common StockholdersNet Income
-42.58M-51.79M-35.58M-52.30M-41.38M-38.83M-44.19M-64.90M-60.21M-66.64M-65.65M-65.10M-97.12M-89.54M-115.36M-110.86M-108.04M-111.95M-120.85M-178.56M
Additional items
EPS (Basic)
-0.83-1.02-0.69-1.01-0.80-0.75-0.78-1.08-0.99-1.12-0.81-0.70-0.96-0.95-1.05-0.97-0.76-0.87-0.73-1.08
EPS (Diluted)
-0.83-1.02-0.69-1.01-0.80-0.75-0.78-1.08-0.99-1.12-0.81-0.70-0.96-0.95-1.05-0.97-0.76-0.87-0.73-1.08
Shares Outstanding
51.32M50.90M51.60M51.68M51.80M51.98M56.33M59.84M61.11M59.68M81.04M92.51M100.88M94.14M109.91M113.87M141.81M128.44M165.04M165.45M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
51.32M50.90M51.60M51.68M51.80M51.98M56.33M59.84M61.11M59.68M81.04M92.51M100.88M94.14M109.91M113.87M141.81M128.44M165.04M165.45M
EBITDA
-42.47M-51.61M-35.36M-52.26M-41.88M-39.76M-45.05M-66.34M-61.87M-67.29M-68.76M-71.56M-105.17M-96.63M-121.87M-115.29M-113.39M-115.61M-124.68M-181.06M
Interest ExpensesInt Expense
0.09M2.90M

Dyne Therapeutics Income Statement API

Pull Dyne Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=DYN&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY